Novartis PKC412 (midostaurin) new drug application (NDA) has received Priority Review from the US Food and Drug Administration (FDA).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug is an investigational, oral, multi-targeted kinase inhibitor in development to treat acute myeloid leukaemia (AML) in newly diagnosed adults with an FMS-like tyrosine kinase-3 (FLT3) mutation and for advanced systemic mastocytosis (SM).

Additionally, the FDA has accepted for review the company's premarket approval application (PMA) for the PKC412 (midostaurin) FLT3 companion diagnostic, developed in partnership with Invivoscribe Technologies.

The European Medicines Agency (EMA) has already accepted the marketing authorisation application for PKC412 to treat AML and SM.

See Also:

Novartis Oncology chief executive officer Bruno Strigini said: "FLT3-mutated AML and advanced SM are devastating and rare diseases, with significant unmet needs due to limited existing treatment options.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"This regulatory designation signifies the importance of midostaurin as a potential therapy for these patients who haven't had the benefit of targeted medicines."

The NDA submission for PKC412 consists of data from the largest clinical trials performed to date in each indication.

"This regulatory designation signifies the importance of midostaurin as a potential therapy for these patients who haven't had the benefit of targeted medicines."

Based on the data from the Phase III RATIFY trial (CALGB 10603) conducted in patients with FLT3-mutated AML, the drug was granted Breakthrough Therapy designation by the FDA.

The data indicated that the overall survival improved in patients treated with PKC412 and chemotherapy combination compared to patients treated with placebo and chemotherapy combination.

A Phase II single-arm study to examine the efficacy of PKC412 in patients with advanced SM demonstrated an overall response rate of 60% with a median duration of response of 24.1 months and a median overall survival of 28.7 months.

Novartis has launched a Global Individual Patient Programme (compassionate use programme) and an Expanded Treatment Protocol in the US, to provide access to PKC412 to eligible patients with newly diagnosed AML and advanced SM as the drug is still under evaluation.

Image: Bone marrow aspirate showing acute myeloid leukaemia. Photo: courtesy of VashiDonsk.